Everolimus improves progression-free survival for patients with rare pancreatic cancer
Wednesday, February 9, 2011 - 18:01
in Health & Medicine
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center.
